Latest Conference

Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.

At IDWeek 2022, Erica Stohs, MD, MPH, presented surprising findings about unnecessary antibiotics in a cohort coinfected with COVID-19 and pneumonia.

The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

There is a significant need for C difficile treatments that don’t destroy the microbiome.

Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”

Breakthrough COVID-19 infections were rare in fully vaccinated individuals, but the average breakthrough occurred just under 50 days after complete vaccination.

At IDWeek 2022, antimicrobial stewardship was front and center. However, not all tests are created equal.

There is an evolution of thinking about how this is treated and investigational therapies are looking to help these patients improve not only their medical conditions but give them back their quality-of-life.

The Novavax booster dose administered in a small study induced more robust antibody responses and its safety profile was considered favorable.

Antimicrobial stewardship works, one IDWeek 2022 study found.

A retrospective cohort study looked at the addition of utilizing a rapid test for gram-positive blood cultures and if time to diagnosis reduced vancomycin duration.

Distance to the clinic negatively impacted whether the HCV-positive individual attended their first HCV visit.

The phase 2, randomized, placebo-controlled, dose-finding trial evaluated the mRNA-based cytomegalovirus vaccine, which features a lipid nanoparticle formulation.

A Health-Related Quality of Life questionnaire designed to gather data on an investigational microbiota therapeutic demonstrated patients felt better about their conditions.

Shionogi shared positive clinical cure rates from their ongoing trial of Fetroja (cefiderocol) for difficult-to-treat Gram-negative infections.

Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.

At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.

After 5 years of treatment, fostemsavir improved immunologic response and virologic outcome in patients with highly resistant HIV infection.

A clinician discusses the disease burden of reoccurring CDI, but sees a silver lining in the new investigational therapies potentially changing the treatment paradigm for the better.

A clinician is advocating for incorporating diagnostic stewardship practices within antimicrobial stewardship programs, which could someday lead to best practice guidelines on a larger scale.

Utilizing a newer technology, investigators wanted to see if a reduction in time led to clinically significant antimicrobial adjustments.

A multicenter study looked at treating these infections with omadacycline.

The investigational, fully human IgG1 monoclonal antibody ADG20 prevented and treated infection with COVID-19 variants of concern.

A medical center wanted to review prescribing and documentation practices for their pharmacists.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2 antibiotics.